Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00301522 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,108
- Enrollment target
NCT00301522 is a Phase 2 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,108 participants.
The verdict
NCT00301522, a Phase 2 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,108 participants
- Enrollment target
Study Summary
The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple overlapping stents in the treatment of de novo coronary artery lesions
Interventions
- DEVICE Express2
- DEVICE TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,108 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00301522
The ClinicalTrials.gov registry entry for NCT00301522 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Express2 is the first listed.
NCT00301522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00301522 about?
NCT00301522 is a clinical study titled "Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions". The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple overlapping stents in the treatment of de novo coronary artery lesions
What is the current status of trial NCT00301522?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,108 participants. The study started on 2003-02. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00301522?
The interventions under investigation include: Express2 (DEVICE), TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation (DEVICE).
Who is sponsoring clinical trial NCT00301522?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.